Clinical trial · Observational
Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity
Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity in Normal Women With Cytology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The only malignancy screening test among gynecological cancers is cervical cancer. Cytology examination and Hpv typing with smear are used as screening tests. Hpv positivity is detected in more than 90% of cervical cancers. However, only the Hpv 16-18 type positive patients undergo colposcopy in the routine screening program. Patients with Smear negative, Type 16-18 high-risk Hpv positivity are evaluated by quota after 1 year. the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 Hpv positivity and type 16-18 high-risk Hpv positivity and to find out whether there was any difference between them. In this way, other high-risk Hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Neoplasm | Cervical Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Human Papilloma Virus | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| colposcopy and colposcopic biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Genotype of HR-HPV 16/18
- description
- Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy
- interventionNames
- Diagnostic Test: colposcopy and colposcopic biopsy
- label
- Genotype of HR-HPV Non-16/18
- description
- Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy
- interventionNames
- Diagnostic Test: colposcopy and colposcopic biopsy
Primary outcomes (2)
- measure
- Genotype of HR-HPV 16/18
- timeFrame
- 1 MONTH
- description
- Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV 16/18
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * 20-65 years old * patients with normal smear Exclusion Criteria: * Patients with invasive cervical cancer, * HIV-positive patients, * ASCUS and more risky premalignant lesions in cytology, * Over the age of 65 and * Patients under 20 years of age, * patients with another known gynecological malignancy
References
Publications (0)
Data not yet available